mhurhangee/ep-ind-claims huggingface dataset:
A fuel supply system for use in a gas turbine engine, said fuel supply system comprising: a fuel manifold; a shutoff valve coupled in flow communication with said fuel manifold and positioned upstream from said fuel manifold, wherein said shutoff valve is configured to actuate into a closed position when the gas turbine engine is operating at an overspeed condition; and characterized in further comprising a relief valve coupled in flow communication with said fuel manifold, wherein said relief valve is configured to release fuel from within said fuel manifold when said shutoff valve is in the closed position, and when a pressure within said fuel manifold is greater than a first predetermined threshold. a fuel manifold; a shutoff valve coupled in flow communication with said fuel manifold and positioned upstream from said fuel manifold, wherein said shutoff valve is configured to actuate into a closed position when the gas turbine engine is operating at an overspeed condition; and characterized in further comprising a relief valve coupled in flow communication with said fuel manifold, wherein said relief valve is configured to release fuel from within said fuel manifold when said shutoff valve is in the closed position, and when a pressure within said fuel manifold is greater than a first predetermined threshold.
Spotlight for generating a visible light stream on a ceiling, comprising an illuminant for generating artificial light in the visible range and an optical member adapted to shape the visible light stream from the light generated by the illuminant, the optical member being designed to define a light distribution curve of the light generated by the illuminant in such a way that a lighting object having a homogeneous luminance density can be generated on the ceiling, characterized in that the optical member is designed to shape the light generated by the illuminant in such a way that the visible light stream has a focal point which is spaced apart from the illuminant and the optical member in a radiation direction such that the visible light stream is a cross beam. define a light distribution curve of the light generated by the illuminant in such a way that a lighting object having a homogeneous luminance density can be generated on the ceiling, characterized in that the optical member is designed to shape the light generated by the illuminant in such a way that the visible light stream has a focal point which is spaced apart from the illuminant and the optical member in a radiation direction such that the visible light stream is a cross beam.
A wireless system for training and monitoring the behavior of an animal by a wireless mobile device comprising: an animal-worn device comprising: a casing, a processor positioned within the casing having pre-programmed instructions; one or more inputs; one or more outputs and a transceiver to communicate with the wireless mobile device via Bluetooth or Wifi; and a pre-programmed computer application configured to run on the wireless mobile device, wherein the processor positioned within the casing is configured to receive signals from the wireless mobile device and wherein the animal-worn device is configured to send data to the wireless mobile device for display on the wireless mobile device characterized in that the wireless system further comprises a remote server configured to receive and analyze input data from the one or more inputs of the animal-worn device, wherein the remote server is configured to tailor new firmware to be downloaded by the animal-worn device based on results from the analysis of the input data. an animal-worn device comprising: a casing, a processor positioned within the casing having pre-programmed instructions; one or more inputs; one or more outputs and a transceiver to communicate with the wireless mobile device via Bluetooth or Wifi; and a casing, a processor positioned within the casing having pre-programmed instructions; one or more inputs; one or more outputs and a transceiver to communicate with the wireless mobile device via Bluetooth or Wifi; and a pre-programmed computer application configured to run on the wireless mobile device, wherein the processor positioned within the casing is configured to receive signals from the wireless mobile device and wherein the animal-worn device is configured to send data to the wireless mobile device for display on the wireless mobile device characterized in that the wireless system further comprises a remote server configured to receive and analyze input data from the one or more inputs of the animal-worn device, wherein the remote server is configured to tailor new firmware to be downloaded by the animal-worn device based on results from the analysis of the input data.
A human antibody, or antigen binding fragment thereof, specific for human CD40 comprising the CDRs of: (a) SEQ ID NOs 13, 14, 15, 16, 17 and 18 (CDRs of antibody 1132/1133); or (b) SEQ ID NOs 1, 2, 3, 4, 5 and 6 (CDRs of antibody 1146/1147); or (c) SEQ ID NOs 19, 20, 21, 22, 23 and 24 (CDRs of antibody 1148/1149); or (d) SEQ ID NOs 37, 38, 39, 40, 41 and 42 (CDRs of antibody 1136/1137); wherein the antibody or fragment thereof comprises: (i) a heavy chain variable region amino acid sequence having at least 90% amino acid sequence identity to a sequence of SEQ ID NO: 65, 61, 67 or 73; and (ii) a light chain variable region amino acid sequence having at least 90% amino acid sequence identity to a sequence of SEQ ID NO: 66, 62, 68 or 74. (a) SEQ ID NOs 13, 14, 15, 16, 17 and 18 (CDRs of antibody 1132/1133); or (b) SEQ ID NOs 1, 2, 3, 4, 5 and 6 (CDRs of antibody 1146/1147); or (c) SEQ ID NOs 19, 20, 21, 22, 23 and 24 (CDRs of antibody 1148/1149); or (d) SEQ ID NOs 37, 38, 39, 40, 41 and 42 (CDRs of antibody 1136/1137); (i) a heavy chain variable region amino acid sequence having at least 90% amino acid sequence identity to a sequence of SEQ ID NO: 65, 61, 67 or 73; and (ii) a light chain variable region amino acid sequence having at least 90% amino acid sequence identity to a sequence of SEQ ID NO: 66, 62, 68 or 74.
A method for identifying an electrical noise propagation path through an object from a source of periodic electrical noise comprising the steps of: a) positioning an electric noise sensor of a noise measurement device at a selected area on the object, the noise sensor generating an output signal to the noise measurement device representative of the magnitude of electrical noise, b) generating a trigger signal in synchronism with the source of periodic electrical noise, c) connecting the trigger signal to the noise measurement device to initiate an electrical noise reading from the sensor by the noise measurement device, the noise measurement device generating an output signal as noise data, d) recording the noise data output from the measurement device associated with the location information of the selected area, e) moving the sensor to a different selected area, and f) reiterating steps a) - e). a) positioning an electric noise sensor of a noise measurement device at a selected area on the object, the noise sensor generating an output signal to the noise measurement device representative of the magnitude of electrical noise, b) generating a trigger signal in synchronism with the source of periodic electrical noise, c) connecting the trigger signal to the noise measurement device to initiate an electrical noise reading from the sensor by the noise measurement device, the noise measurement device generating an output signal as noise data, d) recording the noise data output from the measurement device associated with the location information of the selected area, e) moving the sensor to a different selected area, and f) reiterating steps a) - e).
A method to determine an effective initial dosage of glyceryl tri-[4-phenylbutyrate] (HPN-100) for a patient in need of treatment for a nitrogen retention disorder comprising: determining a target urinary phenylacetyl glutamine (PAGN) output based on a target nitrogen output; and calculating an effective initial dosage of glyceryl tri-[4-phenylbutyrate] (HPN-100) to produce the target PAGN output, wherein the effective initial dosage is calculated based on a mean conversion of glyceryl tri-[4-phenylbutyrate] (HPN-100) to urinary PAGN of 60% to 75%. determining a target urinary phenylacetyl glutamine (PAGN) output based on a target nitrogen output; and calculating an effective initial dosage of glyceryl tri-[4-phenylbutyrate] (HPN-100) to produce the target PAGN output, wherein the effective initial dosage is calculated based on a mean conversion of glyceryl tri-[4-phenylbutyrate] (HPN-100) to urinary PAGN of 60% to 75%.
A system for analyzing a gas mixture, comprising: a filter (135, 171); a trap; a chromatographic column; a detector; and a pump; wherein a first gas flow path is formed by fluid connection of the trap and the pump, wherein the pump is situated downstream of the trap; and wherein a second gas flow path is formed by fluid connection of the filter, the trap, the chromatographic column, the detector, and the pump, wherein the pump is situated downstream of the filter, the trap, the chromatographic column and the detector; and further wherein the gas mixture is air. a filter (135, 171); a trap; a chromatographic column; a detector; and a pump; wherein a first gas flow path is formed by fluid connection of the trap and the pump, wherein the pump is situated downstream of the trap; and wherein a second gas flow path is formed by fluid connection of the filter, the trap, the chromatographic column, the detector, and the pump, wherein the pump is situated downstream of the filter, the trap, the chromatographic column and the detector; and further wherein the gas mixture is air. wherein a first gas flow path is formed by fluid connection of the trap and the pump, wherein the pump is situated downstream of the trap; and wherein a second gas flow path is formed by fluid connection of the filter, the trap, the chromatographic column, the detector, and the pump, wherein the pump is situated downstream of the filter, the trap, the chromatographic column and the detector; and further wherein the gas mixture is air.
A medical device adapted to be positioned in relation to an incision made in the abdominal wall of the patient, the medical device comprising an external portion configured to remain external to the body of the patient during a surgical procedure, and an internal sealing device configured to be placed on the inside of the incision during the surgical procedure, to seal against the abdominal wall, the medical device further comprises a connecting member configured to connect the external portion to the internal sealing device, and wherein the connecting member is adapted to retract the incision, wherein the internal sealing device comprises an internal vacuum sealing member (2505' i) adapted to be positioned inside the body of the patient, the internal vacuum sealing member being adapted to apply a pressure below atmospheric pressure between the medical device and human tissue of an inner surface of the abdominal wall.
An oncolytic virus for use in a method of treating cancer, wherein the method comprises administering the oncolytic virus, an inhibitor of the indoleamine 2,3-dioxygenase pathway and a further antagonist of an immune co-inhibitory pathway, or an agonist of an immune co-stimulatory pathway to a patient.
A method of manufacturing a bone substitute structure for reconstruction of bone material in a patient, the method comprises the steps of: I. providing data reflecting a cavity in a bone of a patient; II. defining and modelling a three dimensional structure corresponding to the cavity in the bone; and III. providing an individualized bone substitute structure, corresponding to the defined and modeled three dimensional structure in step II, characterized in that in step III the individualized bone substitute structure is provided by combining calcium phosphate cement, growth factors and the patient's own un-coagulated blood, where the individualized bone substitute is obtained by using a rapid prototype machine to generate the individualized bone substitute by additive layer manufacturing, wherein a layer upon layer sequence of the calcium phosphate cement, the individualized growth factors and the individualized un-coagulated blood prints the individualized bone substitute structure, and where the rapid prototype machine comprises at least a first printing tube for the calcium phosphate, a second printing tube for the individualized un-coagulated blood and a third printing tube for the growth factors, wherein these at least three printing tubes are computer controlled regarding flow-rate and the layer upon layer sequence. I. providing data reflecting a cavity in a bone of a patient; II. defining and modelling a three dimensional structure corresponding to the cavity in the bone; and III. providing an individualized bone substitute structure, corresponding to the defined and modeled three dimensional structure in step II, characterized in that in step III the individualized bone substitute structure is provided by combining calcium phosphate cement, growth factors and the patient's own un-coagulated blood, where the individualized bone substitute is obtained by using a rapid prototype machine to generate the individualized bone substitute by additive layer manufacturing, wherein a layer upon layer sequence of the calcium phosphate cement, the individualized growth factors and the individualized un-coagulated blood prints the individualized bone substitute structure, and where the rapid prototype machine comprises at least a first printing tube for the calcium phosphate, a second printing tube for the individualized un-coagulated blood and a third printing tube for the growth factors, wherein these at least three printing tubes are computer controlled regarding flow-rate and the layer upon layer sequence.
Vehicle tyre having a tread with profile blocks, a carcass ply, a tyre belt, a tyre inner side and sidewalls, wherein a tyre sensor for measuring a profile depth is arranged in the vehicle tyre, a tyre sensor in the form of an ultrasonic device is arranged on the tyre inner side opposite the tread, wherein a multiplicity of ultrasonic waves are sent in the direction of the profile blocks of the tread by the ultrasonic device, wherein the profile depth of the vehicle tyre is determined by way of a transit time measurement of the reflected ultrasonic waves at the boundary surface between the ambient air and the surface of the profile blocks, characterized in that the ultrasonic device comprises an ultrasonic transmitter, wherein the ultrasonic transmitter sends short wave packets with 5 to 10 oscillations. wherein a tyre sensor for measuring a profile depth is arranged in the vehicle tyre, a tyre sensor in the form of an ultrasonic device is arranged on the tyre inner side opposite the tread, wherein a multiplicity of ultrasonic waves are sent in the direction of the profile blocks of the tread by the ultrasonic device, wherein the profile depth of the vehicle tyre is determined by way of a transit time measurement of the reflected ultrasonic waves at the boundary surface between the ambient air and the surface of the profile blocks, characterized in that the ultrasonic device comprises an ultrasonic transmitter, wherein the ultrasonic transmitter sends short wave packets with 5 to 10 oscillations.
A fixing device (20; 20A) to fix a toner image on a sheet of recording media, comprising: a flexible endless belt that is configured to rotate in a predetermined direction, and has an inner circumferential surface; a rotary member that is configured to contact an outer circumferential surface of the belt; a fixed member fixed inside the belt to press against the rotary member via the belt, forming a nip portion therebetween which is configured to have the sheet transported through; the fixed member, a surface of which includes a fluorine-containing surface layer that is configured to slidingly contact the inner circumferential surface of the belt; a lubricant, applied between the fluorine-containing surface layer of the fixed member and the inner circumferential surface of the belt; and a heat source (25; 50) to heat at least one of the belt and the rotary member, whereinat least one of the fluorine-containing surface layers (21 a; 26a) covering the inner circumferential surface of the belt and the fixed member has a surface energy greater than a surface tension of the lubricant, characterized in that the inner circumferential surface of the belt includes a fluorine-containing surface layer and that one of the fluorine-containing surface layers (21a; 26a) covering the inner circumferential surface of the belt and the fixed member is porous. a flexible endless belt that is configured to rotate in a predetermined direction, and has an inner circumferential surface; a rotary member that is configured to contact an outer circumferential surface of the belt; a fixed member fixed inside the belt to press against the rotary member via the belt, forming a nip portion therebetween which is configured to have the sheet transported through; the fixed member, a surface of which includes a fluorine-containing surface layer that is configured to slidingly contact the inner circumferential surface of the belt; a lubricant, applied between the fluorine-containing surface layer of the fixed member and the inner circumferential surface of the belt; and a heat source (25; 50) to heat at least one of the belt and the rotary member, whereinat least one of the fluorine-containing surface layers (21 a; 26a) covering the inner circumferential surface of the belt and the fixed member has a surface energy greater than a surface tension of the lubricant, characterized in that the inner circumferential surface of the belt includes a fluorine-containing surface layer and that one of the fluorine-containing surface layers (21a; 26a) covering the inner circumferential surface of the belt and the fixed member is porous.
A GRP inhibitor or a GRPR antagonist, or a combination thereof, for use in i) reducing a virally-induced inflammatory response in a subject infected with a virus; ii) reducing virally-induced lung damage in a subject infected with a virus; iii) inhibiting virally-induced lethality in a subject infected with a virus and at risk for virally-induced lethality; iv) treating viral infection in a subject infected with a virus; or v) treating viral pneumonia in a subject having viral pneumonia, wherein the subject is infected with an influenza virus, wherein the influenza virus is an Influenza A virus, an Influenza B virus, an Influenza C virus or an Influenza D virus, wherein the GRP inhibitor is one or more of the mouse anti-GRP neutralizing monoclonal antibody 2A11 (MoAb 2A11) and the small-molecule inhibitors NSC77427, NSC54671, NSC112200, and 2,5-dibromo-3,6-dimethylcyclohexa-2,5-diene-1,4-dione, and wherein the GRPR antagonist is the water-soluble peptide BW2258U89. i) reducing a virally-induced inflammatory response in a subject infected with a virus; ii) reducing virally-induced lung damage in a subject infected with a virus; iii) inhibiting virally-induced lethality in a subject infected with a virus and at risk for virally-induced lethality; iv) treating viral infection in a subject infected with a virus; or v) treating viral pneumonia in a subject having viral pneumonia, wherein the subject is infected with an influenza virus, wherein the influenza virus is an Influenza A virus, an Influenza B virus, an Influenza C virus or an Influenza D virus, wherein the GRP inhibitor is one or more of the mouse anti-GRP neutralizing monoclonal antibody 2A11 (MoAb 2A11) and the small-molecule inhibitors NSC77427, NSC54671, NSC112200, and 2,5-dibromo-3,6-dimethylcyclohexa-2,5-diene-1,4-dione, and wherein the GRPR antagonist is the water-soluble peptide BW2258U89.
A method for reducing the pH of an aqueous system comprising contacting an acid composition with an internal surface of a piece of equipment, wherein the acid composition comprises a salt of a nitrogen base having a fluoro-inorganic anion, wherein the piece of equipment is an evaporator or a steam generator used in a geothermal surface system, a thermal recovery system, a sugar production system, or an ethanol production system.
Method of starting a machine comprising a plurality of modules, each module having a standard run-up time until optimum operating conditions are obtained, characterized in that the method comprises the steps of: - acquisition for each module of an initial state at a time T0 and a run-up time to reach the optimum operating conditions from the time T0; - identification of a slow module having the longest run-up time and determining a time T1 of optimum operation, following run-up, at which said slow module has its optimum operating conditions; - for each module other than the slow module, establishing a starting or run-up time set point for which its optimum operating conditions are reached only at the time T1 or in the immediate vicinity of the time T1. - acquisition for each module of an initial state at a time T0 and a run-up time to reach the optimum operating conditions from the time T0; - identification of a slow module having the longest run-up time and determining a time T1 of optimum operation, following run-up, at which said slow module has its optimum operating conditions; - for each module other than the slow module, establishing a starting or run-up time set point for which its optimum operating conditions are reached only at the time T1 or in the immediate vicinity of the time T1.
A pathogen-inactivated cryoprecipitate composition comprising fibrinogen for use in treating a subject suffering from bleeding, wherein the pathogen-inactivated cryoprecipitate has been thawed at least 24 hours prior to infusion into the subject, and wherein the pathogen-inactivated cryoprecipitate has been prepared by a method comprising: a) preparing a cryoprecipitate from pathogen-inactivated plasma, wherein the pathogen-inactivated plasma has a volume of at least 550mL and less than 650mL; b) freezing the cryoprecipitate; and c) thawing the frozen cryoprecipitate, wherein the resulting cryoprecipitate composition of step c) comprises at least 750 mg of fibrinogen when tested at least 3 days and within 5 days after thawing and storage at room temperature. a) preparing a cryoprecipitate from pathogen-inactivated plasma, wherein the pathogen-inactivated plasma has a volume of at least 550mL and less than 650mL; b) freezing the cryoprecipitate; and c) thawing the frozen cryoprecipitate,